Arthrofibrosis Clinical Trial
Official title:
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
Recent research has focused on methods to mitigate scar tissue formation and arthrofibrosis following surgery in hopes that patients may attain maximal range of motion goals, avoid manipulation and secondary surgery (i.e. revision arthroplasty), and improve their function. The synovial fluid milieu has also highlighted the role of local biochemical markers that may be implicated in the development of arthrofibrosis. Losartan is an angiotensin receptor blocker with inhibitory effects on transforming growth factor beta (TGF-b), largely implicated in tissue repair and fibrosis by way of SMAD protein signaling suppression, and has been used in orthopaedic sports medicine to prevent stiffness following hip arthroscopy. To date, this has not commonly been used at NYU Langone in orthopedic surgery. The purpose of this study is to evaluate the efficacy of losartan use pre- and post-operatively on range of motion and the incidence of manipulation under anesthesia following total knee arthroplasty.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04082533 -
Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)
|
Phase 4 | |
| Active, not recruiting |
NCT03598829 -
A Prospective Clinical Trial Comparing Serum Mast Cell Tryptase (SMCT) Levels to Arthrofibrosis Rates Among Primary Total Knee Arthroplasty (TKA) Patients
|
||
| Completed |
NCT04019847 -
STAK Tool for Treatment of Arthrofibrosis Post Total Knee Replacement
|
N/A | |
| Not yet recruiting |
NCT04360928 -
Knee Split Comparison After ACL Reconstruction
|
N/A |